1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide

• ChemBase编号: 129463
• 分子式: C25H32F3N3O4
• 平均质量: 495.5344896
• 单一同位素质量: 495.23449118
• SMILES: FC(F)(F)COc1ccccc1OCCN[C@H](C)Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO
• Canonical SMILES: OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N
• InChI: InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
• InChIKey: PNCPYILNMDWPEY-QGZVFWFLSA-N

名称和登记号

名称

• IUPAC标准名: 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
• IUPAC传统名: silodosin
• 别名: KAD-3213, KMD-3213; Silodosin; 2,3-Dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide; (R)-1-(3-Hydroxypropyl)-5-[2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]indoline-7-carboxamide; KAD 3213; KMD 3213; Silodosin; Urief

登记号

• CAS号: 160970-54-7
• PubChem SID: 162223757
• PubChem CID: 5312125
• ATC码: G04CA04
• CHEMBL: 24778
• Chemspider ID: 4471557
• IUPHAR配体索引: 493
• 美国药典/FDA物质标识码: CUZ39LUY82
• 维基百科标题: Silodosin

理论计算性质

• Acid pKa: 14.865219
• 质子受体: 6
• 质子供体: 3
• LogD (pH = 5.5): -0.1458398
• LogD (pH = 7.4): 0.82869637
• Log P: 3.0467358
• 摩尔折射率: 128.9196 cm^3
• 极化性: 47.85751 Å^3
• 极化表面积: 97.05 Å^2
• 可自由旋转的化学键: 14
• 里宾斯基五规则: true

分子性质

药理学性质

• 给药途径: Oral
• 生物利用度: 32%
• 排泄: Renal and fecal
• 半衰期: 13±8 hours
• 代谢: Hepatic glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement
• 蛋白结合率: 97%
• 法定药品分级: Rx-only
• 妊娠期药物分类: B (US); Not for use in women

详细说明

Toronto Research Chemicals - S465000

An α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.

参考文献

• Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995)
• Murata, S., et al.: J. Urol., 164, 578 (1995)